Antiviral treatment for pandemic influenza: Assessing potential repercussions using a seasonally forced SIR model

Journal of Theoretical Biology

Volumn 289, Issue 1, 2011, Pages 259-268

  Towers, S ^a   Vogt Geisse, K ^a,b   Zheng, Y ^a   Feng, Z ^a  

^a PURDUE UNIVERSITY   (United States)

^b UNIVERSIDAD ADOLFO IBÁÑEZ   (Chile)

Author keywords

Antiviral treatment model; Epidemic model; Epidemic size; Pandemic influenza model; Seasonally forced transmission

Indexed keywords

DISEASE CONTROL; DISEASE TRANSMISSION; DISEASE TREATMENT; DRUG PRESCRIBING; DRUG RESISTANCE; EPIDEMIC; HEALTH POLICY; INFLUENZA; PUBLIC HEALTH; VACCINE;

2009 H1N1 INFLUENZA; ANTIVIRAL RESISTANCE; ANTIVIRAL THERAPY; ARTICLE; CONTROLLED STUDY; DISEASE MODEL; EPIDEMIC; INFECTION CONTROL; MATHEMATICAL MODEL; PANDEMIC; PANDEMIC INFLUENZA; PREDICTION; PREVALENCE; PRIORITY JOURNAL; SEASONAL VARIATION; SIMULATION; SUSCEPTIBLE INFECTED RECOVERED MODEL; VIRUS TRANSMISSION;

ANTIVIRAL AGENTS; DISEASE SUSCEPTIBILITY; HUMANS; INFLUENZA A VIRUS, H1N1 SUBTYPE; INFLUENZA, HUMAN; MODELS, BIOLOGICAL; PANDEMICS; SEASONS;

EID: 80054051287     PISSN: 00225193     EISSN: 10958541     Source Type: Journal    
DOI: 10.1016/j.jtbi.2011.08.011     Document Type: Article

References (25)

1. Alexander M.E., Dietrich S.M., Hua Y., Moghadas S.M. A comparative evaluation of modelling strategies for the effect of treatment and host interactions on the spread of drug resistance. Journal of Theoretical Biology 2009, 259:253-263.
2. Arino J., Bowman C.S., Moghadas S.M. Antiviral resistance during pandemic influenza: implications for stockpiling and drug use. BMC Infectious Diseases 2009, 9:8.
3. Bacaer, N., Dads, E.H.A., 2010. Genealogy with seasonality, the basic reproduction number, and the influenza pandemic. Journal of Mathematical Biology 62 (5), 741-762.
4. Bacaer N., Gomes G.M. On the final size of epidemics with seasonality. Bulletin of Mathematical Biology 2009, 71:1954-1966.
5. Carrat F., et al. Time lines of infection and disease in human influenza: a review of volunteer challenge studies. American Journal of Epidemiology 2008, 167(7):775-785.
6. Colizza V., Barrat A., Barthelemy M., Valleron A.-J., Vespignani A. Modeling the worldwide spread of pandemic influenza: baseline case and containment interventions. PloS Medicine 2007, 4(1):e13.
7. Dushoff J., Plotkin J.B., Viboud C., Earn D.J., Simonsen L. Mortality due to influenza in the United States. American Journal of Epidemiology 2006, 163(2):181-187.
8. Elder A.G., et al. Incidence and recall of influenza in a cohort of Glasgow healthcare workers during the 1993-4 epidemic: results of serum testing and questionnaire. British Medical Journal 1996, 313(7067):1241.
9. Feng, Z., Towers, S., Yang, Y. Modeling the effects of vaccination and treatment on pandemic influenza. American Association of Pharmaceutical Science Journal, in press, http://doi:10.1208/s12248-011-9284-7.
10. Ferguson N.M., Galvani A.P., Bush R.M. Ecological and immunological determinants of influenza evolution. Nature 2003, 422:428-433.
11. Fraser C., et al. Pandemic potential of a strain of influenza A(H1N1): early findings. Science 2009, 1557:324.
12. King J.C., Haugh C.J., Dupont W.D., Thompson J.M., Wright P.F., Edwards K.M. Laboratory and epidemiological assessment of a recent influenza B outbreak. Journal of Medical Virology 1988, 25(3):361-368.
13. Lee S., Chowell G., Castillo-Chavez C. Optimal control for pandemic influenza: the role of limited antiviral treatment and isolation. Journal of Theoretical Biology 2010, 265(2):136-150.
14. Ling L.M., et al. Effects of early oseltamivir therapy on viral shedding in 2009 pandemic influenza A (H1N1) virus infection. Clinical Infectious Diseases 2010, 50:963-969.
15. Moghadas S.M. Management of drug resistance in the population: influenza as a case study. Proceedings of the Royal Society B 2008, 275:1163-1169.
16. Moscona A. Neuraminidase inhibitors for influenza. New England Journal of Medicine 2005, 353(13):1363-1373.
17. Qiu Z., Feng Z. Transmission dynamics of an influenza model with vaccination and antiviral treatment. Bulletin of Mathematical Biology 2010, 72(1):1-33.
18. Qiu Z., Feng Z. Dynamics of an epidemic model with targeted antiviral prophylaxis. Journal of Biological Dynamics 2010, 4(5):506-526.
19. Qiu, Z., Feng, Z., 2010c. Transmission dynamics of an influenza model with age of infection and antiviral treatment. Journal of Dynamics and Differential Equations 22 (4), 823-851.
20. Towers S., Feng Z. Pandemic H1N1 influenza: predicting the course of pandemic and assessing the efficacy of the planned vaccination programme in the United States. Eurosurveillance 2009, 14(41).
21. Treanor J.J., et al. Efficacy and safety of the oral neuraminidase inhibitor oseltamivir in treating acute influenza. Journal of the American Medical Association 2000, 283(8):1016-1024.
22. U.S. Centers for Disease Control: Weekly Influenza Surveillance Report 2009-2010 Influenza Season, http://www.cdc.gov/flu/weekly/weeklyarchives2009-2010/weekly20.htm.
23. Velasco-Hernández J.X., Leite M.C.A. A model for the A(H1N1) epidemic in Mexico, including social isolation. Salud Publica de Mexico 2011, 53:40-47.
24. World Health Organization, 2010. WHO Guidelines for Pharmacological Management of Pandemic A(H1N1) 2009 and Other Influenza Viruses, February.
25. Yoshida M., et al. Seasonal influenza surveillance using prescription data for anti-influenza medications. Japanese Journal of Infectious Diseases 2009, 62:233-235.